아코다 테라퓨틱스(Accorda Therapeutics)
US ˙ NasdaqGS ˙ US00484M7002
이 기호는 더 이상 활성화되지 않습니다.

SecurityACOR / Acorda Therapeutics, Inc.
InstitutionElkfork Partners LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Elkfork Partners LLC closes position in ACOR / Acorda Therapeutics, Inc.

On November 14, 2019 - Elkfork Partners LLC filed a 13F-HR form disclosing ownership of 0 shares of Acorda Therapeutics, Inc. (US:ACOR) valued at $0 USD as of September 30, 2019. The entity filed a previous 13F-HR on August 13, 2019 disclosing 8,932 shares of Acorda Therapeutics, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2019-11-14 2019-09-30 13F Acorda Therapeutics COM 00484M106 0 -8,932 -100.00 0 -100.00
2019-08-13 2019-06-30 13F Acorda Therapeutics COM 00484M106 8,932 2,068 30.13 68 -25.27 0.0017
2019-05-13 2019-03-31 13F Acorda Therapeutics COM 00484M106 6,864 0 0.00 91 -14.95 0.0023
2019-02-13 2018-12-31 13F Acorda Therapeutics COM 00484M106 6,864 0 0.00 107 -20.74 0.0030
2018-11-14 2018-09-30 13F Acorda Therapeutics COM 00484M106 6,864 0 0.00 135 -31.47 0.0032
2018-08-13 2018-06-30 13F Acorda Therapeutics COM 00484M106 6,864 0 0.00 197 21.60 0.0051
2018-05-10 2018-03-31 13F Acorda Therapeutics COM 00484M106 6,864 0 0.00 162 10.20 0.0044
2018-02-24 2017-12-31 13F/A-1 Acorda Therapeutics COM 00484M106 6,864 2,464 56.00 147 41.35 0.0040
2018-02-22 2017-12-31 13F Acorda Therapeutics COM 00484M106 4,992 592 107
2017-11-14 2017-09-30 13F Acorda Therapeutics COM 00484M106 4,400 770 21.21 104 46.48 0.0030
2017-08-14 2017-06-30 13F Acorda Therapeutics COM 00484M106 3,630 1,716 89.66 71 77.50 0.0021
2017-05-03 2017-03-31 13F Acorda Therapeutics COM 00484M106 1,914 110 6.10 40 17.65 0.0012
2017-02-10 2016-12-31 13F Acorda Therapeutics COM 00484M106 1,804 34
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.